Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00098813
Other study ID # NCI-2012-01458
Secondary ID 04-059N01CM62206
Status Completed
Phase Phase 2
First received December 8, 2004
Last updated May 13, 2014
Start date October 2004
Est. completion date August 2009

Study information

Verified date October 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well romidepsin works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine. Romidepsin may stop the growth of tumor cells by blocking the some of the enzymes needed for cell growth. It may also help radioactive iodine and chemotherapy work better by making tumor cells more sensitive to the drug


Description:

PRIMARY OBJECTIVES:

I. Determine the antitumor activity of romidepsin (depsipeptide), in terms of the proportion of patients achieving a complete or partial response or disease stabilization, in patients with progressive recurrent and/or metastatic non-medullary thyroid carcinoma that is refractory to radioactive iodine (RAI).

II. Determine the safety and tolerability of this drug in these patients.

SECONDARY OBJECTIVES:

I. Document changes in RAI uptake by comparing pre- and post-treatment RAI scans in patients treated with this drug.

II. Evaluate changes in the expression of the Na+/I- symporter (NIS) in tumors, as measured by immunohistochemistry on pre- and post-treatment biopsy specimens; and real time reverse transcriptase polymerase chain reaction (RT-PCR) for NIS mRNA on pre- and post-treatment changes biopsy specimens.

III. Determine post-treatment changes in serum thyroglobulin in patients treated with this drug.

IV. Correlate changes in post-treatment positron-emission tomography scans with whole-body RAI scans in patients treated with this drug.

OUTLINE:

Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of unacceptable toxicity or disease progression.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date August 2009
Est. primary completion date August 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically or cytologically confirmed non-medullary thyroid carcinoma, including the following cell types:

- Papillary

- Follicular

- Variants of papillary or follicular

- Hürthle cell

- Recurrent and/or metastatic disease

- Measurable disease

- At least 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan

- Progressive disease during or after prior treatment, as defined by >= 1 of the following criteria:

- Presence of new or progressive lesions on CT scan or MRI

- New lesions on bone or positron-emission tomography scan

- Rising thyroglobulin level

- Minimum of 3 consecutive rises with an interval of >= 1 week between each determination

- Refractory to radioactive iodine (RAI)

- Absent or insufficient RAI-uptake documented by whole-body RAI scan within the past 6 months

- At least 1 lesion with absent RAI-uptake required for insufficient uptake

- No known brain metastases

- Performance status - Karnofsky 60-100%

- WBC >= 3,000/mm^3

- Absolute neutrophil count >= 1,500/mm^3

- Platelet count >= 100,00/mm^3

- Bilirubin normal

- AST and ALT =< 2.5 times upper limit of normal

- Chronic active viral hepatitis allowed provided patient is clinically stable and fulfills liver function eligibility criteria

- Creatinine normal

- Creatinine clearance >= 60 mL/min

- QTc =< 480 msec by ECG

- ST segment depression < 2 mm

- LVEF >= 50 % by echocardiogram

- No left ventricular hypertrophy, as defined by end-diastolic wall thickness > 12 mm in both the left ventricular posterior wall as well as septum or restrictive cardiomyopathy

- No history of any of the following cardiac diseases:

- Canadian Cardiovascular Society (CCS) class II-IV angina pectoris

- Myocardial infarction within the past 12 months

- Sustained ventricular tachycardia, ventricular fibrillation, Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator

- Any cardiac arrhythmia requiring digitalis or another antiarrhythmic medication other than a beta blocker or calcium channel blocker

- No uncontrolled hypertension (i.e., blood pressure >= 160/95)

- Mobitz II second degree block in patients who do not have a pacemaker

- First degree or Mobitz I second degree block, bradyarrhythmias or sick sinus syndrome require Holter monitoring and evaluation by cardiology

- Uncontrolled dysrhythmias

- No history of congenital long QT syndrome

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Thyroid stimulating hormone normal or suppressed

- No history of allergic reaction attributed to compounds of similar chemical or biologic composition to FR901228

- No ongoing or active infection

- No psychiatric illness or social situation that would preclude study participation

- No other concurrent uncontrolled illness

- At least 4 weeks since prior biologic or targeted agents (e.g., interferon alfa, thalidomide, octreotide, or cetuximab)

- No concurrent antineoplastic biologic agents

- No prior FR901228 (depsipeptide)

- No prior cytotoxic chemotherapy

- Cytotoxic chemotherapy as a radiosensitizer allowed provided >= 3 months since prior administration

- No other concurrent antineoplastic chemotherapy

- Not specified

- At least 4 weeks since prior external beam radiation therapy

- Documented disease progression required if patient received external beam radiotherapy to index lesions

- At least 3 months since prior RAI therapy

- Diagnostic studies using =< 12 mCi of RAI are not considered RAI therapy

- No concurrent antineoplastic radiotherapy

- At least 2 weeks since prior anticancer cyclooxygenase-2 (COX-2) inhibitors, isotretinoin, or complementary medications

- At least 4 weeks since prior tyrosine kinase inhibitors (e.g., gefitinib or erlotinib)

- No other concurrent investigational agents

- No other concurrent anticancer therapy

- No concurrent drugs known to have histone deacetylase inhibitor activity (e.g., valproic acid)

- No concurrent combination anti-retroviral therapy for HIV-positive patients

- No concurrent hydrochlorothiazide

- No concurrent treatment dose warfarin

- No concurrent agents that cause QTc prolongation

- Concurrent daily aspirin given after myocardial infarction or COX-2 inhibitors at standard anti-inflammatory or pain doses allowed

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
romidepsin
Given IV
Other:
laboratory biomarker analysis
Correlative studies
Procedure:
positron emission tomography
Correlative studies

Locations

Country Name City State
United States Memorial Sloan-Kettering Cancer Center at Suffolk Commack New York

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor Major Response Rate (Including Stable Disease) as Measured by RECIST Criteria From start of treatment to 8 weeks No
See also
  Status Clinical Trial Phase
Completed NCT02152137 - Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Terminated NCT00095693 - Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Phase 2
Completed NCT00470496 - Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Phase 1
Active, not recruiting NCT01723202 - Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Phase 2
Completed NCT00085293 - Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Phase 2
Recruiting NCT04892303 - Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer Phase 1
Terminated NCT00126568 - Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Completed NCT00519896 - Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Phase 2
Completed NCT01502410 - Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Phase 2
Completed NCT01413113 - Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery Phase 1
Completed NCT00134043 - Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Phase 2
Completed NCT00118248 - Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Phase 2
Completed NCT00104871 - Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Phase 2
Completed NCT00068497 - Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer N/A
Completed NCT00004074 - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Phase 1